Background: Molecular targeted chemotherapies have been shown to significantly improve
the outcomes of patients who have cancer, but they often cause cardiovascular side effects …

Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of
malignancies, but it causes a dose-related cardiotoxicity that can lead to heart failure in a …

Cardiotoxicity is a major cause of high attrition rates among newly developed drugs.
Moreover, anti-cancer treatment-induced cardiotoxicity is one of the leading reasons of …

Treatment with trastuzumab, a humanized monoclonal antibody directed against the
extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), very …

Cardiotoxicity is one of the most serious side effects of cancer chemotherapy. Current
approaches to monitoring of chemotherapy‐induced cardiotoxicity (CIC) as well as model …

Aims An improved understanding of the pathophysiology of trastuzumab-mediated
cardiotoxicity is required to improve outcomes of patients with human epidermal growth …

Cardiotoxicity is a major side effect of the chemotherapeutic drug doxorubicin (Dox), which is
further exacerbated when it is combined with trastuzumab, a standard care approach for …

It is now well recognized that many lifesaving oncology drugs may adversely affect the heart
and cardiovascular system, including causing irreversible cardiac injury that can result in …

Doxorubicin is a highly efficacious anti-cancer drug but causes cardiotoxicity in many
patients. The mechanisms of doxorubicin-induced cardiotoxicity (DIC) remain incompletely …

Abstract Background MANTICORE 101-Breast (Multidisciplinary Approach to Novel
Therapies in Cardiology Oncology Research) is a randomized trial to determine if …